title: New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents.
abstract: Ankylosing spondylitis (AS) and axial spondyloarthritis (ax SpA) are chronic inflammatory diseases mainly involving the axial skeleton. Pharmacological treatments for AS and ax SpA usually include local glucocorticoid injections, NSAIDs and anti-TNFα agents. Since around 30% to 40% of patients are non responders or intolerant to anti-TNFα agents, we need new therapeutic options for AS and ax SpA. Areas covered: This review describes the new biological agents that can be used or are in development for AS or ax SpA as well as emerging synthetic targeted drugs. Expert opinion: Based on the rationale of the involvement of the IL-23/Th17 axis in AS, novel biological agents have been developed and include secukinumab, an anti-IL-17A agent and ustekinumab, an anti-IL-23 antibody. New compounds in the class of synthetic drugs are apremilast, a PDE4 inhibitor, and inhibitors of kinase pathways. Secukinumab gave positive results in the treatment of AS. Ustekinumab yielded promising results in AS in an open labeled study. Apremilast is not effective in AS while results with kinase inhibitors are preliminary. Future studies will clarify the place of secukinumab in the therapeutic management of AS, its influence on radiographic progression and its effects on the non radiographic form of the disease.
authors.affiliation: a INSERM CIC-1431 , University Hospital of Besançon, Clinical Investigation Center in Biotherapy , Besançon , France.|b Fédération Hospitalo-Universitaire INCREASE , University Hospital of Besançon , Besançon , France.|c Department of Rheumatology , University Hospital of Besançon , Besançon , France.|d Department of Therapeutics and UPRES EA 4266: 'Pathogenic agents and Inflammation' , University of Bourgogne Franche-Comté , Besançon , France.
authors.forename: Eric
authors.initials: E
authors.lastname: Toussirot
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors; D053759:Interleukin-23 / Q000037:antagonists & inhibitors; D016032:Randomized Controlled Trials as Topic; D025241:Spondylarthritis / Q000188:drug therapy* / Q000276:immunology; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D000069549:Ustekinumab / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C508717:IL17A protein, human; D020381:Interleukin-17; D053759:Interleukin-23; C439524:TNF protein, human; D014409:Tumor Necrosis Factor-alpha; C555450:secukinumab; D000069549:Ustekinumab
keywords: Axial spondyloarthritis; IL-23; Th17; apremilast; secukinumab; ustekinumab